Increased expression of the RNA‑binding motif protein 47 predicts poor prognosis in non‑small‑cell lung cancer

Li,Ruilei; Li,Heng; Ge,Chunlei; Fu,Qiaofen; Li,Zhen; Jin,Yarong; Tan,Qinghua; Zhu,Zhitao; Zhang,Zhiwei; Dong,Suwei; Li,Gaofeng; Song,Xin

doi:10.3892/ol.2020.11417

Increased expression of the RNA‑binding motif protein 47 predicts poor prognosis in non‑small‑cell lung cancer

Authors:
- Ruilei Li
- Heng Li
- Chunlei Ge
- Qiaofen Fu
- Zhen Li
- Yarong Jin
- Qinghua Tan
- Zhitao Zhu
- Zhiwei Zhang
- Suwei Dong
- Gaofeng Li
- Xin Song
View Affiliations

Affiliations: Department of Cancer Biotherapy Center, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan 650118, P.R. China, Department of Chest Surgery, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan 650118, P.R. China, Department of Biotherapy, The Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai 201805, P.R. China
Published online on: February 20, 2020 https://doi.org/10.3892/ol.2020.11417
Pages: 3111-3122
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of cancer‑associated mortality worldwide. In China, in particular, lung cancer mortality has markedly increased and is likely to continue to rise. RNA‑binding proteins are pivotal to the development and progression of a variety of cancer types, including non‑small cell lung cancer (NSCLC). RNA‑binding motif protein 47 (RBM47) has been found to act as a tumor suppressor in breast cancer and NSCLC. However, to the best of our knowledge, RBM47 expression in NSCLC tissues has yet to be investigated. Analysis via the online database, Gene Expression Omnibus, revealed that RBM47 was upregulated in NSCLC and associated with pathological type, suggesting that RBM47 may play different roles in lung adenocarcinoma and lung squamous cell carcinoma. In the present study, the expression of RBM47 was examined by immunohistochemistry in 175 pairs of tumor and adjacent non‑cancerous tissues resected from patients with NSCLC. The results indicated that the expression of RBM47 was significantly increased in NSCLC samples compared with that in the matched non‑cancerous samples. Furthermore, RBM47 expression was higher in Xuanwei compared with that in non‑Xuanwei NSCLC, suggesting that RBM47 is a more sensitive biomarker in Xuanwei NSCLC, and that it may serve as a candidate therapeutic target. In addition, RBM47 expression was associated with the pathological type, however not with the age, sex, lymph node metastasis, pT stage or pathological Tumor‑Node‑Metastasis stage of the patients. The increased expression level of RBM47 may indicate a worse overall survival rate for patients with NSCLC. In addition, multivariate survival analysis showed that the Xuanwei area is associated with poor prognosis for patients with NSCLC. In conclusion, the present study revealed that the upregulation of RBM47 accelerated the malignant progression of NSCLC, indicating that RBM47 may be a potential biomarker for NSCLC progression and a therapeutic target for NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Sun KX, Zheng RS, Zeng HM, Zhang SW, Zou XN, Gu XY, Xia CF, Yang ZX, Li H, Chen WQ and He J: The incidence and mortality of lung cancer in China, 2014. Zhonghua Zhong Liu Za Zhi. 40:805–811. 2018.(In Chinese). PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Chen W, Zheng R, Zeng H and Zhang S: Epidemiology of lung cancer in China. Thorac Cancer. 6:209–215. 2015. View Article : Google Scholar : PubMed/NCBI
5	Nakanishi Y, Chen S, Inutsuka S, Ma Y, Jiang X, Hara N, Sera N and Tokiwa H: Possible role of indoor environment and coal combustion emission in lung carcinogenesis in Fuyuan County, China. Neoplasma. 44:69–72. 1997.PubMed/NCBI
6	Chen G, Sun X, Ren H, Wan X, Huang H, Ma X, Ning B, Zou X, Hu W and Yang G: The mortality patterns of lung cancer between 1990 and 2013 in Xuanwei, China. Lung Cancer. 90:155–160. 2015. View Article : Google Scholar : PubMed/NCBI
7	Wu H, Meng S, Xu Q, Wang X, Wang J, Gong R, Song Y, Duan Y and Zhang Y: Gene expression profiling of lung adenocarcinoma in Xuanwei, China. Eur J Cancer Prev. 25:508–517. 2016. View Article : Google Scholar : PubMed/NCBI
8	Mumford JL, He XZ, Chapman RS, Cao SR, Harris DB, Li XM, Xian YL, Jiang WZ, Xu CW, Chuang JC, et al: Lung cancer and indoor air pollution in Xuan Wei, China. Science. 235:217–220. 1987. View Article : Google Scholar : PubMed/NCBI
9	Jiang CL, He SW, Zhang YD, Duan HX, Huang T, Huang YC, Li GF, Wang P, Ma LJ, Zhou GB and Cao Y: Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 8:1369–1391. 2017.PubMed/NCBI
10	He XZ, Chen W, Liu ZY and Chapman RS: An epidemiological study of lung cancer in Xuan Wei County, China: Current progress. Case-control study on lung cancer and cooking fuel. Environ Health Perspect. 94:9–13. 1991. View Article : Google Scholar : PubMed/NCBI
11	Lan Q, Chapman RS, Schreinemachers DM, Tian LW and He XZ: Household stove improvement and risk of lung cancer in Xuanwei, China. J Natl Cancer Inst. 94:826–835. 2002. View Article : Google Scholar : PubMed/NCBI
12	Yang J, Li G, Huang Y, Ye L, Zhou Y, Zhao G, Lei Y, Chen X, Wang K, Chen Y, et al: Association of inorganics accumulation with the activation of NF-κB signaling pathway and the iNOS expression of lung tissue in xuanwei lung cancer patients. Zhongguo Fei Ai Za Zhi. 19:30–37. 2016.(In Chinese). PubMed/NCBI
13	Wakelee H, Kelly K and Edelman MJ: 50 Years of progress in the systemic therapy of non-small cell lung cancer. Am Soc Clin Oncol Educ Book. 177–189. 2014. View Article : Google Scholar : PubMed/NCBI
14	Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower M, et al: NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. 16:807–821. 2018. View Article : Google Scholar : PubMed/NCBI
15	Chen Z, Fillmore CM, Hammerman PS, Kim CF and Wong KK: Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
16	Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, et al: Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 30:1653–1659. 2019. View Article : Google Scholar : PubMed/NCBI
17	Grelet S and Howe PH: hnRNP E1 at the crossroads of translational regulation of epithelial-mesenchymal transition. J Cancer Metastasis Treat. 5(pii): 162019.PubMed/NCBI
18	Sherman EJ, Mitchell DC and Garner AL: The RNA-binding protein SART3 promotes miR-34a biogenesis and G1 cell cycle arrest in lung cancer cells. J Biol Chem. 294:17188–17196. 2019. View Article : Google Scholar : PubMed/NCBI
19	Jung JH, Lee H, Cao B, Liao P, Zeng SX and Lu H: RNA-binding motif protein 10 induces apoptosis and suppresses proliferation by activating p53. Oncogene. Oct 7–2019.(Epub ahead of print).
20	Pereira B, Billaud M and Almeida R: RNA-binding proteins in cancer: Old players and new actors. Trends Cancer. 3:506–528. 2017. View Article : Google Scholar : PubMed/NCBI
21	Zhang Y, Yang L, Ling C and Heng W: HuR facilitates cancer stemness of lung cancer cells via regulating miR-873/CDK3 and miR-125a-3p/CDK3 axis. Biotechnol Lett. 40:623–631. 2018. View Article : Google Scholar : PubMed/NCBI
22	Zhao W, Lu D, Liu L, Cai J, Zhou Y, Yang Y, Zhang Y and Zhang J: Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) promotes lung tumorigenesis via attenuating p53 stability. Oncotarget. 8:93672–93687. 2017.PubMed/NCBI
23	Guan R, El-Rass S, Spillane D, Lam S, Wang Y, Wu J, Chen Z, Wang A, Jia Z, Keating A, et al: rbm47, a novel RNA binding protein, regulates zebrafish head development. Dev Dyn. 242:1395–1404. 2013. View Article : Google Scholar : PubMed/NCBI
24	Yeganeh M, Seyedjafari E, Kamrani FA and Ghaemi N: RNA-binding protein Rbm47 binds to Nanog in mouse embryonic stem cells. Mol Biol Rep. 40:4391–4396. 2013. View Article : Google Scholar : PubMed/NCBI
25	Fossat N, Tourle K, Radziewic T, Barratt K, Liebhold D, Studdert JB, Power M, Jones V, Loebel DA and Tam PP: C to U RNA editing mediated by APOBEC1 requires RNA-binding protein RBM47. EMBO Rep. 15:903–910. 2014. View Article : Google Scholar : PubMed/NCBI
26	Vanharanta S, Marney CB, Shu W, Valiente M, Zou Y, Mele A, Darnell RB and Massagué J: Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. Elife. 3:2014. View Article : Google Scholar : PubMed/NCBI
27	Sakurai T, Isogaya K, Sakai S, Morikawa M, Morishita Y, Ehata S, Miyazono K and Koinuma D: RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma. Oncogene. 36:50832017. View Article : Google Scholar : PubMed/NCBI
28	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
29	Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, et al: NCCN guidelines insights: Non-small cell lung cancer, version 1.2020. J Natl Compr Canc Netw. 17:1464–1472. 2019. View Article : Google Scholar : PubMed/NCBI
30	Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, Dong SW, Li RL, Zhao MY, Zhen Y, Yu XL, et al: Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol. 8:222015. View Article : Google Scholar : PubMed/NCBI
31	Suwei D, Liang Z, Zhimin L, Ruilei L, Yingying Z, Zhen L, Chunlei G, Zhangchao L, Yuanbo X, Jinyan Y, et al: NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin. J Hematol Oncol. 8:1202015. View Article : Google Scholar : PubMed/NCBI
32	Zeng B, Ge C, Li R, Zhang Z, Fu Q, Li Z, Lin Z, Liu L, Xue Y, Xu Y, et al: Knockdown of microsomal glutathione S-transferase 1 inhibits lung adenocarcinoma cell proliferation and induces apoptosis. Biomed Pharmacother. 121:1095622019. View Article : Google Scholar : PubMed/NCBI
33	Lian S, Li L, Zhou Y, Liu Z and Wang L: The co-expression networks of differentially expressed RBPs with TFs and LncRNAs related to clinical TNM stages of cancers. PeerJ. 7:e76962019. View Article : Google Scholar : PubMed/NCBI
34	Liu G, Zhang Q, Xia L, Shi M, Cai J, Zhang H, Li J, Lin G, Xie W, Zhang Y and Xu N: RNA-binding protein CELF6 is cell cycle regulated and controls cancer cell proliferation by stabilizing p21. Cell Death Dis. 10:6882019. View Article : Google Scholar : PubMed/NCBI
35	Hong YG, Xu GS, Yu GY, Zhou JD, Liu QZ, Ni JS, Yan HL, Zhang W and Hao LQ: The RNA binding protein neuro-oncological ventral antigen 1 (NOVA1) regulates IL-6 mRNA stability to enhance JAK2-STAT3 signaling in CRC. Surg Oncol. 31:67–74. 2019. View Article : Google Scholar : PubMed/NCBI
36	Busà R, Paronetto MP, Farini D, Pierantozzi E, Botti F, Angelini DF, Attisani F, Vespasiani G and Sette C: The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells. Oncogene. 26:4372–4382. 2007. View Article : Google Scholar : PubMed/NCBI
37	Vo DT, Subramaniam D, Remke M, Burton TL, Uren PJ, Gelfond JA, de Sousa Abreu R, Burns SC, Qiao M, Suresh U, et al: The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis. Am J Pathol. 181:1762–1772. 2012. View Article : Google Scholar : PubMed/NCBI
38	Wurth L, Papasaikas P, Olmeda D, Bley N, Calvo GT, Guerrero S, Cerezo-Wallis D, Martinez-Useros J, García-Fernández M, Hüttelmaier S, et al: UNR/CSDE1 drives a post-transcriptional program to promote melanoma invasion and metastasis. Cancer Cell. 30:694–707. 2016. View Article : Google Scholar : PubMed/NCBI
39	Hopkins TG, Mura M, Al-Ashtal HA, Lahr RM, Abd-Latip N, Sweeney K, Lu H, Weir J, El-Bahrawy M, Steel JH, et al: The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucleic Acids Res. 44:1227–1246. 2016. View Article : Google Scholar : PubMed/NCBI
40	Yong H, Zhu H, Zhang S, Zhao W, Wang W, Chen C, Ding G, Zhu L, Zhu Z, Liu H, et al: Prognostic value of decreased expression of RBM4 in human gastric cancer. Sci Rep. 6:282222016. View Article : Google Scholar : PubMed/NCBI
41	Glisovic T, Bachorik JL, Yong J and Dreyfuss G: RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett. 582:1977–1986. 2008. View Article : Google Scholar : PubMed/NCBI
42	Biswas J, Patel VL, Bhaskar V, Chao JA, Singer RH and Eliscovich C: The structural basis for RNA selectivity by the IMP family of RNA-binding proteins. Nat Commun. 10:44402019. View Article : Google Scholar : PubMed/NCBI
43	Bechara EG, Sebestyén E, Bernardis I, Eyras E and Valcárcel J: RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol Cell. 52:720–733. 2013. View Article : Google Scholar : PubMed/NCBI
44	Hernández J, Bechara E, Schlesinger D, Delgado J, Serrano L and Valcárcel J: Tumor suppressor properties of the splicing regulatory factor RBM10. RNA Biol. 13:466–472. 2016. View Article : Google Scholar : PubMed/NCBI
45	Zhang Z, Huang A, Zhang A and Zhou C: HuR promotes breast cancer cell proliferation and survival via binding to CDK3 mRNA. Biomed Pharmacother. 91:788–795. 2017. View Article : Google Scholar : PubMed/NCBI
46	Mitsunari K, Miyata Y, Asai A, Matsuo T, Shida Y, Hakariya T and Sakai H: Human antigen R is positively associated with malignant aggressiveness via upregulation of cell proliferation, migration, and vascular endothelial growth factors and cyclooxygenase-2 in prostate cancer. Transl Res. 175:116–128. 2016. View Article : Google Scholar : PubMed/NCBI
47	Wang W, Caldwell MC, Lin S, Furneaux H and Gorospe M: HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J. 19:2340–2350. 2000. View Article : Google Scholar : PubMed/NCBI
48	Wu M, Tong CWS, Yan W, To KKW and Cho WCS: The RNA binding protein HuR: A promising drug target for anticancer therapy. Curr Cancer Drug Targets. 19:382–399. 2019. View Article : Google Scholar : PubMed/NCBI
49	Prabhu VV and Devaraj N: Regulating RNA binding motif 5 gene expression-A novel therapeutic target for lung cancer. J Environ Pathol Toxicol Oncol. 36:99–105. 2017. View Article : Google Scholar : PubMed/NCBI
50	Kavianpour M, Ahmadzadeh A, Shahrabi S and Saki N: Significance of oncogenes and tumor suppressor genes in AML prognosis. Tumour Biol. 37:10041–10052. 2016. View Article : Google Scholar : PubMed/NCBI
51	Jiang QQ and Liu WB: miR-25 Promotes Melanoma Progression by regulating RNA binding motif protein 47. Med Sci (Paris). 34 Focus(Issue F1): 59–65. 2018. View Article : Google Scholar
52	Wang TW, Vermeulen RC, Hu W, Liu G, Xiao X, Alekseyev Y, Xu J, Reiss B, Steiling K, Downward GS, et al: Gene-expression profiling of buccal epithelium among non-smoking women exposed to household air pollution from smoky coal. Carcinogenesis. 36:1494–1501. 2015.PubMed/NCBI
53	Wei Y, Zhang F, Zhang Y, Wang X, Xing C, Guo J, Zhang H, Suo Z, Li Y, Wang J, et al: Post-transcriptional regulator Rbm47 elevates IL-10 production and promotes the immunosuppression of B cells. Cell Mol Immunol. 16:580–589. 2019. View Article : Google Scholar : PubMed/NCBI
54	Xuan Y, Wang J, Ban L, Lu JJ, Yi C, Li Z, Yu W, Li M, Xu T, Yang W, et al: hnRNPA2/B1 activates cyclooxygenase-2 and promotes tumor growth in human lung cancers. Mol Oncol. 10:610–624. 2016. View Article : Google Scholar : PubMed/NCBI
55	Wei TY, Juan CC, Hisa JY, Su LJ, Lee YC, Chou HY, Chen JM, Wu YC, Chiu SC, Hsu CP, et al: Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade. Cancer Sci. 103:1640–1650. 2012. View Article : Google Scholar : PubMed/NCBI
56	Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ, Liang SC, Lin CH, Whang-Peng J, Hsu SL, Chen CH and Huang CY: Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics. 8:1402007. View Article : Google Scholar : PubMed/NCBI
57	Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, Lin CW, Shih JY, Yang PC, Hsiao CK, Lai LC and Chuang EY: Identification of a novel biomarker, SEMA5A, for non-smallcell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers Prev. 19:2590–2597. 2010. View Article : Google Scholar : PubMed/NCBI
58	Kuner R, Muley T, Meister M, Ruschhaupt M, Buness A, Xu EC, Schnabel P, Warth A, Poustka A, Sültmann H and Hoffmann H: Global gene expression analysis revealsspecific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer. 63:32–38. 2009. View Article : Google Scholar : PubMed/NCBI
59	Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et al: Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol. 10(28): 4417–4424. 2010. View Article : Google Scholar
60	Lo FY, Chang JW, Chang IS, Chen YJ, Hsu HS, Huang SF, Tsai FY, Jiang SS, Kanteti R, Nandi S, et al: The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization. BMC Cancer. 12:2352012. View Article : Google Scholar : PubMed/NCBI